



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

January 30, 2017

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001

The Manager, Listing Dept.
The National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sirs,

Sub: Press Release

Please find enclosed press release for the financial results for the third quarter and nine months ended December 31, 2016.

Please take the above on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

Encl: A/a



Press Release
For immediate dissemination

Pfizer Limited Revenue at Rs 504 crore for the quarter ended December 31, 2016.

Pfizer Limited announced its results for the quarter and nine months ended December 31, 2016.

Revenue

Revenue for the quarter ended December 31, 2016 is Rs 504 crore as compared to Rs 521 crore in the same period last year.

Revenue for the nine months ended December 31, 2016 is Rs 1570 crore as compared to Rs 1543 crore in the same period last year, reflecting a growth of 2%.

Revenue has been impacted by multiple external factors, viz. pricing notifications during the year, lower sale of Corex and divestiture / sale of certain brands.

Adjusting for the impact of Corex and divestiture / sale of brands, the 'continuing business' delivered a growth of 4%. Within this, the brands that are not under price control reflected a growth of 13% for the quarter.

Discontinuation of Corex Cough Syrup

The Honorable Delhi High Court vide its Judgement dated December 1, 2016, quashed and set aside the Notifications of the Government of India dated March 10, 2016 banning 344 fixed dose combinations, Corex Cough Syrup being one of them. Independent of the favorable judgment, we had undertaken a comprehensive review of our respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, we decided to launch additional products as line extensions while discontinuing the manufacture of Corex Cough Syrup.

Profits before other income, exceptional items and tax

Profit from operations (before other income, exceptional items and tax) for the quarter and nine months is Rs 47 crore and Rs 208 crore respectively, primarily impacted by pricing policy.

Profit after tax

Net Profit after tax (including other comprehensive income) for the quarter is Rs 60.5 crore as against Rs 59.9 crore in the same period last year.

Net Profit after tax (including other comprehensive income) for the half year is Rs 267 crore as against Rs 218 crore in the same period last year, reflecting a growth of 23%.

For more information,

Investors:

Prajeet Nair

Pfizer Limited

Ph.: +91-22-66932352

Email: prajeet.nair@pfizer.com

Media:

Saritha Rajeev Hajare

Pfizer Limited

+ 91 9619990917

saritha.r.hajare@pfizer.com

About Pfizer Limited:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advice may be obtained and necessary due diligence, investigation etc. may be done at your end.